Measles virus takes on ovarian cancer in early trial
NCT ID NCT02364713
First seen Nov 17, 2025 · Last updated Jun 19, 2026 · Updated 28 times
Summary
This phase 2 trial tested a genetically modified measles virus (MV-NIS) against standard chemotherapy in 17 women with ovarian, fallopian, or peritoneal cancer that no longer responded to platinum drugs. The virus was designed to infect and kill cancer cells while leaving healthy cells alone. The study was terminated early, so firm conclusions about effectiveness are not possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN SEROMUCINOUS CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
genetically modified measles virus (MV-NIS)
What this could lead to
If successful, this could point toward a new treatment option for ovarian cancer that has stopped responding to platinum-based chemotherapy.
What could go wrong
This trial was terminated early with only 17 participants, so results are very limited. The virus may not work better than standard chemotherapy and could cause side effects like infection or inflammation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.